Millennium Management’s Aldeyra Therapeutics ALDX Stock Holding History

Millennium Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,200	Closed	-$111K	–	5972
2025 Q3	$111K	Buy	+21,200	New	+$111K	﹤0.01%	5683
2025 Q2	–	Sell	-41,300	Closed	-$237K	–	5824
2025 Q1	$237K	Buy	+41,300	New	+$244K	﹤0.01%	5214
2021 Q1	–	Sell	-200,000	Closed	-$1.37M	–	5857
2020 Q4	$1.37M	Buy	+200,000	New	+$1.4M	﹤0.01%	3513

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management's ALDX Position: Q1 2026 in Review

Millennium Management increased its Aldeyra Therapeutics (ALDX) stake by 2,159% in Q1 2026, buying an estimated $4.17M and bringing the position to 995,243 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Millennium Management first reported a position in ALDX in Q2 2015 and has held it in 43 quarters since. The position peaked at $13.1M in Q3 2018. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Millennium Management held 995,243 shares of Aldeyra Therapeutics worth $1.68M as of Q1 2026.
Millennium Management bought 951,184 Aldeyra Therapeutics shares in Q1 2026, an estimated $4.17M.
Aldeyra Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4022 holding.
Millennium Management first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 43 quarters since.
Millennium Management's Aldeyra Therapeutics position peaked at $13.1M in Q3 2018.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.